AKTS Stock Forecast & Price Target

Aktis Oncology is projected to have a total market value of $1.93B, corresponding to a 12-month price objective of $35 per share, based on a discounted cash flow valuation methodology with a 20% probability of approval for its pipeline products, and a 12% discount rate. Key risks to the company's valuation and price target achievement include potential negative clinical results, delays in advancing pipeline candidates, difficulties obtaining regulatory approvals, and competition in the RIT/RLT market. The company's focus on targeted radiopharmaceuticals for a variety of solid tumors presents an attractive opportunity for growth and impact in the oncology market.

Aktis Oncology is facing significant financial headwinds as its reported net loss for 2025 was $78.34 per share, wider than expected and projected to continue in the near future. While the company has a promising pipeline and upcoming data catalysts, its high operating expenses and lack of revenue from product sales may impede its ability to sustain operations in the long term. With a limited profitability outlook and uncertain future funding, the stock is unattractive for financial analysts.